Compare GLAS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLAS | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.2M | 600.2M |
| IPO Year | 2021 | 2018 |
| Metric | GLAS | ARVN |
|---|---|---|
| Price | $2.37 | $7.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $9.00 | ★ $14.54 |
| AVG Volume (30 Days) | ★ 2.5M | 679.4K |
| Earning Date | 11-16-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $6.93 | $12.96 |
| Revenue Next Year | $21.01 | N/A |
| P/E Ratio | ★ N/A | $4.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $6.74 |
| 52 Week High | $12.70 | $14.22 |
| Indicator | GLAS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 22.56 | 48.35 |
| Support Level | $1.67 | $6.74 |
| Resistance Level | $10.53 | $7.77 |
| Average True Range (ATR) | 0.39 | 0.36 |
| MACD | 0.12 | 0.09 |
| Stochastic Oscillator | 33.91 | 62.79 |
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.